Roche Holding AG agreed to acquire worldwide rights of Codexis Inc.'s EvoT4, an enzyme that is used to analyze a patient's genetic code and how their cells express their genes as proteins.
EvoT4 was developed using Codexis' proprietary protein engineering platform CodeEvolver.
Redwood City, Calif.-based Codexis is a protein engineering company and develops proteins for manufacturing pharmaceuticals, fine chemicals and industrial enzymes.
Financial details of the agreement were not disclosed.